Every material Form 8-K ARDELYX, INC. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ardelyx reported third-quarter 2026 results on November 3, 2026, with total product revenue up 19% to $125.5 million and a net loss narrowing to $0.7 million from $1.0 million a year earlier. The company reiterated its full-year 2026 revenue and operating expense guidance and reported $285.3 million in cash, cash equivalents and short-term investments as of September 30, 2026. Research and development expenses rose 39% and SG&A expenses rose 12% year over year, and the company said the ACCEL Phase 3 trial in chronic idiopathic constipation is fully enrolled.
Total product revenue of $125.5 million for the quarter ended September 30, 2026, versus $105.5 million a year earlier; IBSRELA $96.3 million (up 23%) and XPHOZAH $29.2 million (up 7%).
Net loss of $0.7 million, or $(0.00) per share, versus a net loss of $1.0 million a year earlier; R&D expenses were $25.2 million and SG&A expenses were $93.9 million.
Full-year 2026 guidance reiterated: IBSRELA revenue $350 million to $370 million, XPHOZAH revenue $110 million to $120 million, and operating expenses below $500 million.
Cash and short-term investments of $285.3 million at September 30, 2026, up from $264.7 million at December 31, 2025; topline data from the ACCEL trial expected in the second half of 2027.
Ardelyx disclosed that Chief Commercial Officer Eric Foster notified the company on August 11, 2026, of his decision to resign, effective August 28, 2026. The filing says he is leaving to pursue a new opportunity with a pre-commercial company and that the resignation is not the result of any disagreement with the company. The filing does not name a successor or describe transition arrangements.
Eric Foster gave notice of resignation on August 11, 2026; the resignation is effective August 28, 2026.
Foster is leaving to pursue a new opportunity with a pre-commercial company.
The filing states the resignation is not the result of any disagreement with the company.
Ardelyx reported second-quarter 2026 total product revenue of $118.1 million, up 31% from a year earlier, and a narrower net loss of $16.7 million, or $(0.07) per share. The company cut its full-year 2026 IBSRELA revenue guidance to $350 million to $370 million from $410 million to $430 million, and withdrew its long-term XPHOZAH guidance, citing payor access barriers and evolving market dynamics that matter to shareholders' view of growth timing.
Q2 2026 total product revenue was $118.1 million, up from $90.1 million; IBSRELA $86.2 million (up 33%) and XPHOZAH $31.9 million (up 27%).
Net loss narrowed to $16.7 million, or $(0.07) per share, from $19.1 million, or $(0.08) per share, a year earlier.
FY 2026 IBSRELA revenue guidance revised to $350 million to $370 million from $410 million to $430 million; XPHOZAH FY 2026 guidance reiterated at $110 million to $120 million.
Operating expense guidance lowered to below $500 million from up to $520 million; long-term XPHOZAH guidance withdrawn and timing of the $1 billion IBSRELA target under evaluation.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ARDELYX, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →